ZA201102523B - Isolation and purification of antibodies using protein a affinity chromatography - Google Patents

Isolation and purification of antibodies using protein a affinity chromatography

Info

Publication number
ZA201102523B
ZA201102523B ZA2011/02523A ZA201102523A ZA201102523B ZA 201102523 B ZA201102523 B ZA 201102523B ZA 2011/02523 A ZA2011/02523 A ZA 2011/02523A ZA 201102523 A ZA201102523 A ZA 201102523A ZA 201102523 B ZA201102523 B ZA 201102523B
Authority
ZA
South Africa
Prior art keywords
antibodies
isolation
purification
protein
affinity chromatography
Prior art date
Application number
ZA2011/02523A
Other languages
English (en)
Inventor
Robert K Hickman
Cheryl L Weed
Barbara Perilli-Palmer
Qing Huang
Scott T Ennis
Min W Wan
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41835469&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201102523(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of ZA201102523B publication Critical patent/ZA201102523B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/824—Immunological separation techniques

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA2011/02523A 2008-10-20 2011-04-05 Isolation and purification of antibodies using protein a affinity chromatography ZA201102523B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19675308P 2008-10-20 2008-10-20
PCT/US2009/061329 WO2010141039A1 (en) 2008-10-20 2009-10-20 Isolation and purification of antibodies using protein a affinity chromatography

Publications (1)

Publication Number Publication Date
ZA201102523B true ZA201102523B (en) 2011-12-28

Family

ID=41835469

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/02523A ZA201102523B (en) 2008-10-20 2011-04-05 Isolation and purification of antibodies using protein a affinity chromatography

Country Status (18)

Country Link
US (5) US8895709B2 (OSRAM)
EP (2) EP2350127B1 (OSRAM)
JP (2) JP5808249B2 (OSRAM)
KR (1) KR20110091678A (OSRAM)
CN (2) CN102257006A (OSRAM)
AU (4) AU2009347206C1 (OSRAM)
BR (1) BRPI0920027A2 (OSRAM)
CA (3) CA2911256A1 (OSRAM)
ES (1) ES2535734T3 (OSRAM)
HK (1) HK1209428A1 (OSRAM)
IL (3) IL211918A (OSRAM)
MX (3) MX2011004200A (OSRAM)
NZ (1) NZ592095A (OSRAM)
RU (1) RU2520838C2 (OSRAM)
SG (1) SG10201702922VA (OSRAM)
TW (2) TWI610936B (OSRAM)
WO (1) WO2010141039A1 (OSRAM)
ZA (1) ZA201102523B (OSRAM)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101616758B1 (ko) 2007-12-26 2016-04-29 젠코어 인코포레이티드 ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체
AU2009307737B2 (en) 2008-10-20 2015-07-23 Abbvie Inc. Viral inactivation during purification of antibodies
NZ592095A (en) * 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
US8262912B1 (en) * 2009-06-05 2012-09-11 Tenfold Technologies, LLC Isolated bioactive compounds and method of use
US9056265B2 (en) 2009-06-05 2015-06-16 Tenfold Technologies, LLC Isolated bioactive compounds and method of use
CN102686738A (zh) * 2009-09-01 2012-09-19 弗·哈夫曼-拉罗切有限公司 通过改进的a蛋白洗脱增强的蛋白质纯化
CA2813747A1 (en) * 2010-10-11 2012-04-19 Chen Wang Processes for purification of proteins
CN105107228B (zh) 2010-12-06 2017-03-29 颇尔公司 生物制品的连续加工方法
WO2012125735A1 (en) * 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
JP6024025B2 (ja) * 2011-05-02 2016-11-09 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 少容量投与用のアロタイプ選択抗体の限外濾過濃縮
WO2012160536A1 (en) * 2011-05-26 2012-11-29 Dr Reddy's Laboratories Limited Antibody purification
CN103717284B (zh) * 2011-06-08 2016-02-24 新加坡科技研究局 通过约束共水合色谱纯化生物制品
US20140288278A1 (en) * 2011-10-31 2014-09-25 Joseph Nti-Gyabaah Chromatography process for resolving heterogeneous antibody aggregates
BR112014012005A2 (pt) * 2011-11-21 2017-12-19 Genentech Inc composições, métodos, formulação farmacêutica e artigo
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
EP3184542A1 (en) 2012-05-14 2017-06-28 Novo Nordisk A/S Stabilised protein solutions
US20130336957A1 (en) * 2012-05-21 2013-12-19 Abbvie, Inc. Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
US20140154270A1 (en) * 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US20150133643A1 (en) * 2012-06-06 2015-05-14 Emd Millipore Corporation Low Organic Extractable Depth Filter Media Processed with Solvent Extraction Method
JP6182210B2 (ja) * 2012-06-29 2017-08-16 イー・エム・デイー・ミリポア・コーポレイシヨン タンパク質精製プロセス中のウイルスの不活性化方法
EP2890782A1 (en) 2012-09-02 2015-07-08 AbbVie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CN104603144A (zh) 2012-09-03 2015-05-06 株式会社钟化 混合模式抗体亲和分离基质和使用其的纯化方法及靶分子
PE20191815A1 (es) 2012-09-07 2019-12-27 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
WO2014102814A1 (en) * 2012-12-31 2014-07-03 Intas Biopharmaceuticals Limited Process for the purification of fc fusion proteins
RU2768003C2 (ru) 2013-03-08 2022-03-22 Джензим Корпорейшн Интегрированное непрерывное производство терапевтических белковых лекарственных веществ
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
WO2014159554A1 (en) * 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014142882A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014186350A1 (en) * 2013-05-15 2014-11-20 Medimmune Limited Purification of recombinantly produced polypeptides
KR101569783B1 (ko) * 2013-06-05 2015-11-19 한화케미칼 주식회사 항체의 정제 방법
AR096713A1 (es) * 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
EP3019262A1 (en) 2013-07-12 2016-05-18 Merck Patent GmbH Removal of fragments from a sample containing a target protein using activated carbon
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
NZ756750A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
CN105555795A (zh) 2013-09-17 2016-05-04 株式会社钟化 新抗体纯化方法和由该方法得到的抗体、以及使用了阳离子交换基团的新抗体纯化法和由该方法得到的抗体
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
CN106170298B (zh) 2013-10-16 2024-01-09 前瞻疗法公司 用于提高抗体稳定性的缓冲液制剂
US8946395B1 (en) * 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
IL296754A (en) * 2013-12-27 2022-11-01 Chugai Pharmaceutical Co Ltd A method for isolating an antibody with a low isoelectric point
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
DK3116891T3 (da) 2014-03-10 2020-05-04 Richter Gedeon Nyrt Immunglobulinrensning ved hjælp af forrensningstrin
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US20170183376A1 (en) 2014-06-24 2017-06-29 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
US10329323B2 (en) 2014-07-25 2019-06-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Method for purifying antibodies using PBS
JP6630036B2 (ja) * 2014-09-30 2020-01-15 Jsr株式会社 標的物の精製方法、及び、ミックスモード用担体
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
CN105566442A (zh) * 2014-10-11 2016-05-11 江苏泰康生物医药有限公司 一种降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化工艺
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
MX395730B (es) 2015-03-13 2025-03-25 Bristol Myers Squibb Co Uso de lavados alcalinos durante la cromatografia para remover impurezas.
WO2017027861A1 (en) 2015-08-13 2017-02-16 Amgen Inc. Charged depth filtration of antigen-binding proteins
HK1259368A1 (zh) * 2015-08-20 2019-11-29 F. Hoffmann-La Roche Ag Fkpa的纯化及其用於生产重组多肽的用途
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
MX2018009341A (es) 2016-02-03 2019-05-15 Oncobiologics Inc Formulaciones tamponadas para una mayor estabilidad de anticuerpos.
US11186858B1 (en) 2016-03-15 2021-11-30 Fresenius Kabi Deutschland Gmbh Methods for increasing biosimilarity
MX2018011435A (es) 2016-04-01 2019-01-10 Ucb Biopharma Sprl Metodo para purificacion de proteinas.
IL290358B2 (en) 2016-04-14 2024-03-01 Lonza Ag Preparations and methods for detecting host cell proteins
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
SG11201900201YA (en) 2016-08-16 2019-02-27 Regeneron Pharma Methods for quantitating individual antibodies from a mixture
AU2017350807B2 (en) 2016-10-25 2022-07-07 Regeneron Pharmaceuticals, Inc. Methods and systems for chromatography data analysis
PE20191354A1 (es) * 2016-12-09 2019-10-01 Gliknik Inc Optimizacion de fabricacion de gl-2045, un stradomer multimerizante
KR20190093186A (ko) 2016-12-09 2019-08-08 글리크닉 인코포레이티드 다가 Fc 화합물에 의해 염증성 장애를 치료하는 방법
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
DK3559027T3 (da) 2016-12-23 2022-09-05 Serum Institute Of India Pvt Ltd Fremgangsmåder til forbedring af antistofoproduktivitet i pattedyrecellekultur og minimering af aggregering nedstrøms, formuleringsprocesser og stabile antistofformuleringer opnået deraf
EP3668985B1 (en) 2017-08-17 2021-06-16 Just-Evotec Biologics, Inc. Method of purifying glycosylated protein from host cell galectins and other contaminants
EP3673989B1 (en) * 2017-08-23 2025-06-04 JSR Corporation Ligand-immobilizing carrier, chromatography column, and target substance purification method
CN118416215A (zh) 2017-09-19 2024-08-02 里珍纳龙药品有限公司 减少粒子形成的方法以及由其形成的组合物
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
EP3728288B1 (en) * 2017-12-21 2022-01-19 Genzyme Corporation Methods for enhanced removal of impurities during protein a chromatography
WO2019183334A1 (en) 2018-03-21 2019-09-26 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbents, devices and methods
CN108239146A (zh) * 2018-03-26 2018-07-03 江苏中新医药有限公司 一种高纯度rhNGF的制备方法
LT3781943T (lt) 2018-04-20 2022-07-11 Janssen Biotech, Inc. Chromatografinės kolonos kvalifikavimas gamybinių metodų, skirtų pagaminti anti-il-12/il-23 antikūnų kompozicijas, metu
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
HK40046210A (en) * 2018-08-31 2021-10-29 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CN111072773A (zh) * 2018-10-19 2020-04-28 菲鹏生物股份有限公司 抗体的纯化方法、抗体和应用
CN111153993B (zh) * 2018-11-07 2024-06-28 正大天晴药业集团南京顺欣制药有限公司 抗TNF-α单克隆抗体的制备方法
KR20210096633A (ko) * 2018-11-29 2021-08-05 리폼 바이오로직스, 엘엘씨 단백질 처리를 위한 부형제 화합물
GB201904741D0 (en) * 2019-04-04 2019-05-22 Glaxosmithkline Ip Dev Ltd Novel process
AR119097A1 (es) * 2019-06-05 2021-11-24 Seattle Genetics Inc Métodos de purificación de anticuerpos enmascarados
MX2023003863A (es) * 2020-10-02 2023-04-14 Lilly Co Eli Metodos para reducir el contenido de proteinas de la celula huesped en procesos de purificacion de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteinas de la celula huesped.
WO2023284073A1 (zh) * 2021-07-13 2023-01-19 江苏荃信生物医药股份有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法、抗人ifnar1单克隆抗体浓缩溶液的制备方法以及液体制剂
CN113501857A (zh) * 2021-08-17 2021-10-15 沈阳百发科技有限公司 一种高活性重组蛋白的制备方法
CN114292328B (zh) * 2021-12-30 2025-07-25 武汉原谷生物科技有限责任公司 一种来源于美洲羊驼中天然抗体的纯化方法及其应用
WO2023141612A2 (en) * 2022-01-24 2023-07-27 University Of Florida Research Foundation, Incorporated Point of care testing system for antithrombin iii
CN115073590A (zh) * 2022-07-08 2022-09-20 杭州艾策生物技术有限公司 一种减少单克隆抗体氧化杂质的深层过滤方法
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells

Family Cites Families (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
JPS59156299A (ja) 1983-02-28 1984-09-05 Noda Sangyo Kagaku Kenkyusho Ｎ−アセチルヘキソサミンの定量法及びその定量用試薬
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4534972A (en) 1983-03-29 1985-08-13 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5045468A (en) 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5110913A (en) 1990-05-25 1992-05-05 Miles Inc. Antibody purification method
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ES2287206T3 (es) 1991-03-01 2007-12-16 Dyax Corporation Proceso para el desarrollo de mini-proteinas de union.
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0666312A1 (en) 1994-02-08 1995-08-09 Wolfgang A. Renner Process for the improvement of mammalian cell growth
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5853714A (en) 1995-03-27 1998-12-29 Genetics Institute, Inc. Method for purification of IL-12
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
ES2180689T3 (es) 1996-04-19 2003-02-16 Nestle Sa Linea inmortalizada de celulas epiteliales del colon humano.
AU5082698A (en) 1996-10-23 1998-05-15 Oravax, Inc Heat inactivation of viruses in antibody preparations
ATE256476T1 (de) * 1996-11-15 2004-01-15 Kennedy Inst Of Rheumatology Unterdrückung von tnfalpha und il-12 in der therapie
ES2335365T3 (es) 1996-11-27 2010-03-25 Genentech, Inc. Purificacion por afinidad de polipeptido en una matriz de proteina a.
US6955917B2 (en) * 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
IL121900A (en) 1997-10-07 2001-12-23 Omrix Biopharmaceuticals Ltd A method for the purification of immunoglobulins
US20020045207A1 (en) 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
WO1999032605A1 (en) 1997-12-19 1999-07-01 Novo Nordisk A/S Method for producing heterologous proteins in eukaryotic cells on an industrial scale using nucleotide-manipulating agents
US20030175884A1 (en) 2001-08-03 2003-09-18 Pablo Umana Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
KR20010043323A (ko) 1998-05-06 2001-05-25 제넨테크, 인크. 이온 교환 크로마토그래피에 의한 단백질 정제 방법
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
WO2001023592A2 (en) 1999-09-27 2001-04-05 Genentech, Inc. Methods for making recombinant proteins using apoptosis inhibitors
ES2266159T3 (es) 2000-02-08 2007-03-01 Genentech, Inc. Mejora de la galactosilacion de glicoproteinas recombinantes.
JP2004500086A (ja) 2000-02-10 2004-01-08 アボット・ラボラトリーズ ヒトインターロイキン１８に結合する抗体とその調整方法および使用方法
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
EP1175931A1 (en) 2000-07-25 2002-01-30 Computer Cell Culture Center S.A. Integration of high cell density bioreactor operation with ultra fast on-line downstream processing
US6635448B2 (en) 2000-08-21 2003-10-21 Clonexdevelopment, Inc. Methods and compositions for increasing protein yield from a cell culture
US6693173B2 (en) 2000-12-26 2004-02-17 Alpha Therapeutic Corporation Method to remove citrate and aluminum from proteins
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
EP1970448A1 (en) 2001-05-11 2008-09-17 Kirin Pharma Kabushiki Kaisha Human artificial chromosome containting human antibody lambda light chain and non-human animal containting the human artificial chromosome capable of genetic transmission
NZ530025A (en) 2001-06-05 2005-06-24 Inst Genetics Llc Methods for purifying highly anionic proteins
WO2003029442A1 (en) 2001-10-02 2003-04-10 Novo Nordisk Health Care Ag Method for production of recombinant proteins in eukaryote cells
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
NZ533084A (en) 2001-11-28 2006-02-24 Sandoz Ag Cell culture process
MXPA04006053A (es) 2001-12-21 2005-03-31 Immunex Corp Metodos para purificacion de proteina.
US20030201229A1 (en) 2002-02-04 2003-10-30 Martin Siwak Process for prefiltration of a protein solution
CA2473144C (en) 2002-02-05 2013-05-28 Genentech, Inc. Protein purification
CA2417689C (en) 2002-03-05 2006-05-09 F. Hoffmann-La Roche Ag Improved methods for growing mammalian cells in vitro
US20030190710A1 (en) 2002-03-28 2003-10-09 Devries Ruth L. Control of glycoforms in IgG
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
RU2304587C2 (ru) * 2002-06-10 2007-08-20 Гуд Байотек Копэрейшн СПОСОБ СЕЛЕКТИВНОГО ВЫДЕЛЕНИЯ АНТИТЕЛ IgY ИЗ ЯИЧНОГО ЖЕЛТКА ПТИЦ ОТРЯДА ГУСЕОБРАЗНЫХ (ВАРИАНТЫ)
SI1543106T1 (sl) 2002-07-15 2007-08-31 Immunex Corp Postopki in mediji za nadziranje sialilacije proteinov, ki jih proizvajajo sesalske celice
NZ555692A (en) * 2002-07-19 2009-02-28 Abbott Biotech Ltd Treatment of TNF alpha related disorders
US7067279B1 (en) 2002-08-23 2006-06-27 Immunex Corporation Cell culture performance with betaine
US6974681B1 (en) 2002-08-23 2005-12-13 Immunex Corporation Cell culture performance with vanadate
JP2006508062A (ja) 2002-09-17 2006-03-09 ジーティーシー バイオセラピューティックス インコーポレイテッド 重鎖間ジスルフィド結合を欠く免疫グロブリン分子の単離
US7208585B2 (en) 2002-09-18 2007-04-24 Genencor International, Inc. Protein purification
US20040162414A1 (en) 2002-11-22 2004-08-19 Santora Ling C. Method for reducing or preventing modification of a polypeptide in solution
JP4541157B2 (ja) 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
ES2354610T5 (es) 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
DK1623019T4 (en) 2003-05-15 2017-03-27 Wyeth Llc LIMITED GLUCOSE SUPPLY TO ANIMAL CELL CULTURE
JP4599355B2 (ja) 2003-07-28 2010-12-15 ジェネンテック， インコーポレイテッド プロテインａアフィニティークロマトグラフィーの間のプロテインａの浸出の低減
GB2404665B (en) 2003-08-08 2005-07-06 Cambridge Antibody Tech Cell culture
WO2005035748A1 (en) 2003-10-10 2005-04-21 Novo Nordisk Health Care Ag Method for large-scale production of a polypeptide in eukaryote cells and a culture vessel suitable therefor
KR101221862B1 (ko) 2003-10-27 2013-01-14 와이어쓰 엘엘씨 하이드록시아파타이트 크로마토그래피를 사용한 고분자량응집체의 제거
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
SE0400886D0 (sv) 2004-04-02 2004-04-02 Amersham Biosciences Ab Process of purification
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
MXPA06012676A (es) 2004-05-04 2007-04-02 Novo Nordisk Healthcare Ag Glucoformas o-enlazadas de polipeptidos y metodos de fabricacion de los mismos.
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
DK1807101T3 (en) 2004-09-30 2016-05-23 Bayer Healthcare Llc Devices and methods for integrated continuous production of biological molecules
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
JP2006143601A (ja) 2004-11-16 2006-06-08 Yamato Yakuhin Kk 血液粘度低下剤
US8728828B2 (en) 2004-12-22 2014-05-20 Ge Healthcare Bio-Sciences Ab Purification of immunoglobulins
CN101120085B (zh) 2005-02-11 2011-06-08 诺和诺德医疗保健公司 在包含植物蛋白水解产物的无血清细胞培养液中生产多肽
ES2797480T3 (es) 2005-03-11 2020-12-02 Wyeth Llc Un procedimiento de cromatografía de reparto débil
CN101218247A (zh) 2005-04-11 2008-07-09 米德列斯公司 利用hcic和离子交换层析的蛋白质纯化
WO2006113743A2 (en) 2005-04-18 2006-10-26 Massachusetts Institute Of Technology Compositions and methods for rna interference with sialidase expression and uses thereof
US7247457B2 (en) 2005-04-26 2007-07-24 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Detection and identification of enteroviruses by semi-nested amplification of the enterovirus VP1 protein
EP1888638A2 (en) 2005-06-03 2008-02-20 Genentech, Inc. Method of producing antibodies with modified fucosylation level
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
CN101213211A (zh) 2005-06-17 2008-07-02 惠氏公司 纯化含Fc区蛋白的方法
CN101282990B (zh) 2005-08-26 2013-04-03 阿雷斯贸易股份有限公司 糖基化干扰素-β的制备方法
AR058140A1 (es) 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
AU2006324163B2 (en) 2005-12-08 2013-05-02 Amgen Inc. Improved production of glycoproteins using manganese
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
WO2007117490A2 (en) * 2006-04-05 2007-10-18 Abbott Biotechnology Ltd. Antibody purification
AU2007254141B2 (en) 2006-05-19 2012-10-11 Glycofi, Inc. Erythropoietin compositions
EP2069387A4 (en) 2006-06-14 2011-02-02 Glaxosmithkline Llc METHODS OF PURIFYING ANTIBODIES USING HYDROXYAPATITE CERAMIC
WO2008007280A2 (en) 2006-06-28 2008-01-17 Koninklijke Philips Electronics N.V. Assay system and method
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
CA2661748C (en) 2006-08-28 2016-02-09 Alex Eon-Duval Process for the purification of fc-containing proteins
WO2008031020A2 (en) 2006-09-08 2008-03-13 Wyeth Arginine wash in protein purification using affinity chromatography
CA2842964A1 (en) * 2006-09-13 2008-03-20 Abbvie Inc. Cell culture improvements
US8911964B2 (en) * 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US10982250B2 (en) 2006-09-18 2021-04-20 Genentech, Inc. Methods of protein production
WO2008036899A2 (en) * 2006-09-22 2008-03-27 Amgen Inc. Methods for removing viral contaminants during protein purification
EP2064315B1 (en) 2006-11-03 2015-05-13 Wyeth LLC Glycolysis-inhibiting substances in cell culture
JP5065391B2 (ja) 2006-12-06 2012-10-31 日本ケミカルリサーチ株式会社 ヒトエリスロポエチンの製造方法
WO2008079302A2 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US9012180B2 (en) 2007-03-02 2015-04-21 Wyeth Llc Use of copper and glutamate in cell culture for production of polypeptides
EP2142560A4 (en) * 2007-03-30 2010-12-01 Abbott Lab RECOMBINANT EXPRESSION VECTOR ELEMENTS (REVE) FOR INCREASING THE EXPRESSION OF RECOMBINANT PROTEINS IN HOST CELLS
WO2008121615A2 (en) 2007-03-30 2008-10-09 Medimmune, Inc. Antibody formulation
JP5967861B2 (ja) 2007-04-03 2016-08-10 オキシレイン ユーケー リミテッド 分子のグリコシル化
PT2137655E (pt) 2007-04-16 2012-09-14 Momenta Pharmaceuticals Inc Produtos de glicoproteína definidos e métodos relacionados
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
WO2008135498A2 (en) 2007-05-04 2008-11-13 Novo Nordisk A/S Prevention of protein degradation in mammalian cell cultures
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
AU2008251405B2 (en) 2007-05-11 2012-05-17 Amgen Inc. Improved feed media
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
PL4365189T3 (pl) 2007-07-09 2025-05-26 F. Hoffmann-La Roche Ag Zapobieganie redukcji wiązania disiarczkowego podczas rekombinacyjnego wytwarzania polipeptydów
EP2188371B1 (en) 2007-08-09 2017-12-20 Wyeth LLC Use of perfusion to enhance production of fed-batch cell culture in bioreactors
WO2009058769A1 (en) 2007-10-30 2009-05-07 Schering Corporation Purification of antibodies containing hydrophobic variants
PE20091434A1 (es) 2007-10-30 2009-10-17 Genentech Inc Purificacion de anticuerpos por cromatografia de intercambio cationico
TWM332870U (en) * 2007-11-22 2008-05-21 Delta Electronics Inc Side-edge type backlight module
KR20150080038A (ko) 2007-11-30 2015-07-08 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
SI2235197T1 (sl) 2007-12-27 2017-10-30 Baxalta GmbH Procesi celične kulture
US8093364B2 (en) 2008-01-18 2012-01-10 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
WO2009114641A1 (en) 2008-03-11 2009-09-17 Genentech, Inc. Antibodies with enhanced adcc function
CA2721037C (en) 2008-04-15 2018-05-22 Talecris Biotherapeutics, Inc. Methods for preparing a concentrated plasma product formulation using ultrafiltration/diafiltration
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
EP2331700A2 (en) 2008-08-08 2011-06-15 Biogen Idec MA Inc. Nutrient monitoring and feedback control for increased bioproduct production
DK2848625T3 (da) 2008-08-14 2019-10-07 Genentech Inc Fremgangsmåder til fjernelse af en kontaminant under anvendelse af ion bytningsmembrankromatografi med forskydning af naturligt forekommende proteiner
JP2012503656A (ja) 2008-09-26 2012-02-09 エウレカ セラピューティクス，インコーポレイテッド 変異体グリコシル化パターンを有する細胞株およびタンパク質
AU2009307737B2 (en) 2008-10-20 2015-07-23 Abbvie Inc. Viral inactivation during purification of antibodies
NZ592095A (en) * 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
CA2739077A1 (en) 2008-10-20 2010-04-29 Robert K. Hickman Antibodies that bind to il-18 and methods of purifying the same
WO2010048190A2 (en) 2008-10-20 2010-04-29 Abbott Laboratories Antibodies that bind to il-12 and methods of purifying the same
ES2699434T3 (es) 2008-10-31 2019-02-11 Wyeth Llc Purificación de proteínas ácidas utilizando cromatografía de hidroxiapatita cerámica
CA2744510A1 (en) 2008-12-09 2010-06-17 F.Hoffmann-La Roche Ag Method for obtaining an excipient-free antibody solution
MX2011006654A (es) 2008-12-22 2011-07-12 Hoffmann La Roche Purificacion de inmunoglobulina.
EP2373676B1 (en) 2009-01-08 2017-04-19 GE Healthcare BioProcess R&D AB Separation method using single polymer phase systems
CA2752393C (en) 2009-03-05 2020-01-14 Biogen Idec Ma Inc. Purification of immunoglobulins
CN102365368B (zh) 2009-03-27 2014-07-30 旭化成医疗株式会社 高浓度单克隆抗体溶液中的病毒去除方法
EP2419436A1 (en) 2009-04-13 2012-02-22 Bristol-Myers Squibb Company Protein purification by citrate precipitation
US9034341B2 (en) 2009-04-20 2015-05-19 Transtech Pharma, Llc Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
SG176217A1 (en) 2009-05-28 2011-12-29 Boehringer Ingelheim Int Method for a rational cell culturing process
CA2763164A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
CN107043703B (zh) 2009-07-06 2020-03-27 弗·哈夫曼-拉罗切有限公司 真核细胞的培养方法
MX2012000841A (es) 2009-07-24 2012-02-28 Hoffmann La Roche Optimizacion de la produccion de anticuerpos.
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
SI2462158T1 (en) 2009-08-06 2018-04-30 F. Hoffmann-La Roche Ag Method to improve virus removal in protein purification
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
WO2011024025A1 (en) 2009-08-28 2011-03-03 Avesthagen Limited An erythropoietin analogue and a method thereof
CN102686738A (zh) 2009-09-01 2012-09-19 弗·哈夫曼-拉罗切有限公司 通过改进的a蛋白洗脱增强的蛋白质纯化
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
RU2603055C2 (ru) * 2009-10-20 2016-11-20 Эббви Инк Выделение и очистка антител против il-13 с применением аффинной хроматографии с белком а
WO2011049798A1 (en) 2009-10-20 2011-04-28 Merck Sharp & Dohme Corp. Use of mixed mode chromatography for the capture and purification of basic antibody products
WO2011065940A1 (en) 2009-11-24 2011-06-03 Biogen Idec Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
US20110136682A1 (en) 2009-12-04 2011-06-09 Momenta Pharmaceuticals, Inc. Antennary fucosylation in glycoproteins from cho cells
US8277649B2 (en) 2009-12-14 2012-10-02 General Electric Company Membranes and associated methods for purification of antibodies
CA2784278C (en) 2009-12-18 2019-02-26 Novartis Ag Wash solution and method for affinity chromatography
WO2011087301A2 (ko) 2010-01-15 2011-07-21 성균관대학교산학협력단 기체 및 수분 차단용 그래핀 보호막, 이의 형성 방법 및 그의 용도
MX2012011555A (es) 2010-04-06 2013-01-29 Heliae Dev Llc Metodos y sistemas para aislar aceites ricos en omega-3 y carotenoides de algas.
BR112012025645A2 (pt) 2010-04-07 2017-12-12 Momenta Pharmaceuticals Inc glicanos de alta manose.
LT3330370T (lt) 2010-04-26 2021-06-10 Novartis Ag Cho ląstelių auginimo būdas
CN102858952B (zh) 2010-04-26 2015-10-14 诺瓦提斯公司 改进的细胞培养基
KR20190067277A (ko) 2010-05-28 2019-06-14 제넨테크, 인크. 락테이트 데히드로게나제 및 피루베이트 데히드로게나제 키나제의 발현의 하향조절에 의한 락테이트 수준의 감소 및 폴리펩티드 생산의 증가
EP2601287B1 (en) 2010-08-05 2015-01-07 Amgen Inc. Dipeptides to enhance yield and viability from cell cultures
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
EP2618904A1 (en) * 2010-09-20 2013-07-31 AbbVie Inc. Purification of antibodies using simulated moving bed chromatography
CA2813747A1 (en) * 2010-10-11 2012-04-19 Chen Wang Processes for purification of proteins
CN103154243A (zh) 2010-10-15 2013-06-12 日本化学研究株式会社 糖链的非还原末端为甘露糖残基的糖蛋白的制造方法
EP2450375A1 (en) 2010-11-09 2012-05-09 Sandoz Gmbh Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor
WO2012078376A1 (en) 2010-12-08 2012-06-14 Amgen Inc. Ion exchange chromatography in the presence of an amino acid
WO2012084829A1 (en) 2010-12-21 2012-06-28 F. Hoffmann-La Roche Ag Isoform enriched antibody preparation and method for obtaining it
AU2012226398B9 (en) 2011-03-06 2017-04-13 Merck Serono S.A. Low fucose cell lines and uses thereof
RU2013147609A (ru) 2011-03-25 2015-04-27 Дженентек, Инк. Новые способы очистки белка
EP2511293A1 (en) 2011-04-13 2012-10-17 LEK Pharmaceuticals d.d. A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
WO2012147048A2 (en) 2011-04-29 2012-11-01 Biocon Research Limited Methods for reducing accumulation of lactate during culturing and method for producing polypeptide
US20120283419A1 (en) 2011-05-03 2012-11-08 Avantor Performance Materials, Inc. Separation of protein monomers from aggregates by solid weak anion exchange support functionalized with amine moieties
WO2012158551A1 (en) 2011-05-13 2012-11-22 Biogen Idec Ma Inc. Methods of preventing and removing trisulfide bonds
WO2013006461A1 (en) 2011-07-01 2013-01-10 Biogen Idec Ma Inc. Cholesterol-based media supplementals for cell culture
JP5897708B2 (ja) 2011-07-01 2016-03-30 アムジエン・インコーポレーテツド 哺乳類細胞培養物
CN103717729B (zh) 2011-07-08 2017-11-21 动量制药公司 细胞培养方法
WO2013013013A2 (en) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
CN103890002A (zh) 2011-10-19 2014-06-25 罗切格利卡特公司 岩藻糖基化抗体的分离方法
US9150645B2 (en) * 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9249182B2 (en) * 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9085618B2 (en) * 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same

Also Published As

Publication number Publication date
HK1209428A1 (en) 2016-04-01
AU2009347206A1 (en) 2010-12-09
TW201634476A (zh) 2016-10-01
IL232601A0 (en) 2014-06-30
IL211918A (en) 2016-03-31
MX2011004200A (es) 2011-05-24
AU2015207915A1 (en) 2015-08-20
SG10201702922VA (en) 2017-06-29
RU2011120191A (ru) 2012-11-27
WO2010141039A1 (en) 2010-12-09
AU2009347206A8 (en) 2011-05-26
KR20110091678A (ko) 2011-08-12
JP2012506383A (ja) 2012-03-15
IL244157A0 (en) 2016-04-21
RU2520838C2 (ru) 2014-06-27
BRPI0920027A2 (pt) 2015-10-06
NZ592095A (en) 2013-01-25
US20100135987A1 (en) 2010-06-03
US20150210735A1 (en) 2015-07-30
CA2911256A1 (en) 2010-12-09
ES2535734T3 (es) 2015-05-14
AU2016222301A1 (en) 2016-09-15
MX2018014395A (es) 2020-07-29
MX343087B (es) 2016-10-14
EP2921501A1 (en) 2015-09-23
EP2350127A1 (en) 2011-08-03
CA2738498A1 (en) 2010-12-09
US20170158760A1 (en) 2017-06-08
AU2015207915B2 (en) 2016-06-02
IL211918A0 (en) 2011-06-30
US9018361B2 (en) 2015-04-28
CA2932207A1 (en) 2010-12-09
CN105111309A (zh) 2015-12-02
EP2350127B1 (en) 2015-01-28
AU2015207915C1 (en) 2016-12-08
US8895709B2 (en) 2014-11-25
AU2009347206C1 (en) 2016-12-08
US20160083452A1 (en) 2016-03-24
AU2018203810A1 (en) 2018-06-21
JP5808249B2 (ja) 2015-11-10
US20140255423A1 (en) 2014-09-11
AU2009347206B2 (en) 2015-08-20
TW201024318A (en) 2010-07-01
TWI610936B (zh) 2018-01-11
JP2015042645A (ja) 2015-03-05
CN102257006A (zh) 2011-11-23

Similar Documents

Publication Publication Date Title
IL244157A0 (en) Isolation and purification of antibodies using protein a affinity chromatography
ZA201202720B (en) Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
SG2013061528A (en) Methods for purifying antibodies using protein a affinity chromatography
IL205257A0 (en) Anti-rsv g protein antibodies
ZA201100058B (en) Prostaglandin e2 binding proteins and uses thereof
PL2190984T3 (pl) Sposoby i zestawy do oczyszczania i wykrywania glikozylowanego IgG
IL197479A0 (en) High affinity human antibodies to human il-4 receptor
PL1786273T3 (pl) Schematy sekwencyjnego izolowania i oczyszczania białek sposobem chromatografii powinowactwa
IL215014A0 (en) Antibody molecules having binding specificity for human il-13
EP2184356A4 (en) METHOD FOR BONDING PROTEIN TO MEDIA USING TAMAVIDINE
EP2182003A4 (en) FOR BINDING IMMOBILULATED PEPTIDE
HK1175182A (en) Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
GB0709037D0 (en) Isolation of proteins
IL182717A0 (en) Antibodies to interferon - ??/?? binding protein
GB0608602D0 (en) Analysis of proteins
EP2540742A4 (en) MONOCLONAL ANTIBODIES OF ANTI-CYR61 PROTEIN AND USES THEREOF
AU2009905049A0 (en) Affinity Ligands and Methods for Protein Purification